OncoMatch/Clinical Trials/NCT07230106
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Is NCT07230106 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for prostate cancer.
Treatment: HS-20093 for · SHR3680 Tablet · Abiraterone Tablet · SHR2554 Tablet · Enzalutamide Tablet · Darotamine Capsule — This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: LHRH agonist — ongoing
Ongoing Androgen Deprivation Therapy (ADT) throughout the study period, i.e., continuous treatment with a GnRH agonist or antagonist (chemical castration) or prior bilateral orchiectomy (surgical castration)
Cannot have received: estrogen
Administration of estrogen...within 28 days prior to enrollment
Cannot have received: progesterone
Administration of...progesterone...within 28 days prior to enrollment
Cannot have received: 5-alpha reductase inhibitor
Administration of...5-alpha reductase inhibitors within 28 days prior to enrollment
Cannot have received: herbal medicine with anti-prostate cancer or PSA-lowering effects
Administration of herbal medicines known to have anti-prostate cancer or PSA-lowering effects within 14 days prior to enrollment
Lab requirements
Blood counts
adequate organ function levels at baseline assessment
Kidney function
adequate organ function levels at baseline assessment
Liver function
adequate organ function levels at baseline assessment
Adequate organ function levels at baseline assessment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07230106 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior estrogen, progesterone, 5-alpha reductase inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages